Katrine joined Editas Medicine as Chief Executive Officer in 2014, shortly after the company was founded. Katrine has been part of the biotechnology industry for over 25 years. Prior to joining Editas, Katrine was an Entrepreneur-in-Residence at The Broad Institute, a biomedical and genomic research center, and before that, she was the CEO of Avila Therapeutics (acquired by Celgene). Katrine was also Vice President, Business Development at Adnexus Therapeutics and then Vice President, Strategic Operations after Adnexus’ acquisition by Bristol-Myers Squibb. Earlier, Katrine held several positions at Biogen in Business Development, Commercial Operations, and Portfolio Strategy and was part of the healthcare team at the venture firm Highland Capital Partners. She is a graduate of Cornell University.
In addition to her role at Editas, Katrine currently serves as Chairman of the Board of Genocea Biosciences (NASDAQ: GNCA), Chair of the Emerging Companies Section of the Biotechnology Innovation Organization (BIO) Board of Directors, and is a member of the Board of Directors of Galapagos NV (EURONEXT and NASDAQ: GLPG) and of Massachusetts Eye and Ear.